Comments
Loading...
Amedisys Stock Guidance | NASDAQ:AMED | Benzinga
Amedisys issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 05/03/2023 | AMED | Amedisys | FY | 2023 | $4.14 | $4.36 | $4.25 | $2.25B | $2.27B | $2.26B | Get Alert |
| 02/15/2023 | AMED | Amedisys | FY | 2023 | $4.13 | $4.36 | $4.86 | $2.24B | $2.27B | $2.36B | Get Alert |
| 11/17/2022 | AMED | Amedisys | FY | 2022 | $4.82 | $4.93 | $4.87 | $2.22B | $2.23B | $2.23B | Get Alert |
| 10/26/2022 | AMED | Amedisys | FY | 2022 | $4.82 | $4.93 | $5.28 | $2.22B | $2.23B | $2.29B | Get Alert |
| 07/27/2022 | AMED | Amedisys | FY | 2022 | $5.23 | $5.45 | $5.30 | $2.29B | $2.31B | $2.35B | Get Alert |
| 04/27/2022 | AMED | Amedisys | FY | 2022 | $5.23 | $5.45 | $5.33 | $2.33B | $2.37B | $2.36B | Get Alert |
| 02/23/2022 | AMED | Amedisys | FY | 2022 | $5.23 | $5.45 | $5.84 | $2.33B | $2.37B | $2.37B | Get Alert |
| 11/02/2021 | AMED | Amedisys | FY | 2021 | $5.88 | $5.93 | $6.08 | $2.20B | $2.21B | $2.25B | Get Alert |
| 08/04/2021 | AMED | Amedisys | FY | 2021 | $6.37 | $6.49 | $6.96 | $2.23M | $2.25M | $2.32B | Get Alert |
| 04/28/2021 | AMED | Amedisys | FY | 2021 | $6.85 | $7.07 | $6.37 | $2.30B | $2.34B | $2.30B | Get Alert |
| 02/24/2021 | AMED | Amedisys | FY | 2021 | $6.25 | $6.47 | $6.31 | $2.27B | $2.31B | $2.31B | Get Alert |
| 10/28/2020 | AMED | Amedisys | FY | 2020 | $6.02 | $6.08 | $4.98 | $2.07B | $2.07B | $2.06B | Get Alert |
| 07/28/2020 | AMED | Amedisys | FY | 2020 | $4.84 | $5.06 | $4.54 | $2.04B | $2.07B | $2.04B | Get Alert |
FAQ
What is the most recent guidance for Amedisys (AMED)?
The most recent guidance for Amedisys (AMED) was reported on May 3, 2023 for the full year 2023. The company provided earnings per share guidance in the range of $4.14 to $4.36, compared to the estimated EPS of $4.25. Additionally, Amedisys forecasted revenue between $2.25B and $2.27B for the quarter.
Browse guidance and forecast on all stocks.